Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund News: Bill Ackman, David Einhorn & Aurelius Capital Management

Page 1 of 2

Inside the Trade: What Bill Ackman Sees in Valeant and Allergan (InstitutionalInvestorsAlpha)
When William Ackman took the stage at the AXA Equitable Auditorium in Midtown Manhattan on April 22, investors were still digesting the news that his firm, Pershing Square Capital Management, had amassed a 9.7 percent stake in Allergan, Inc. (NYSE:AGN), an Irvine, California-based specialty pharmaceuticals company. But Ackman’s two- hour, 110-slide PowerPoint presentation had very little to do with Allergan; instead it focused almost entirely on Valeant Pharmaceuticals Intl Inc (NYSE:VRX), a Laval, Quebec-based company with which Pershing Square is teaming up to try to acquire the maker of Botox…

Bill Ackman in crowd

Hedge Fund Compensation Takes a Dive (ai-CIO)
UK-based hedge fund managers have seen a sharp decline in compensation over the last two years, according to salary data tracker Emolument. The median base salary for director-level professionals fell from £120,000 ($199,000) in 2012 to £101,000 in 2013. This year, it has dropped again to £90,000. “Over the last few years since 2008, hedge fund managers have been more willing to show flexibility when it comes to management fees, which is why base salaries have been eroding thus,” said Robert Benson, the data firm’s CEO.

Hedge Fund Manager & “Martha Stewart of Marijuana” Co-Hosts The Global Cannabis Summit (HedgeCo)
Cheryl Shuman, the first Cannabis entrepreneur to manage a $100 million hedge fund to invest in the cannabis businesses, has been called upon to consult and co-host at the GreenRush Financial Conference being held in Seattle, Washington on September 23, 2014. Her private medical cannabis collective, “The Beverly Hills Cannabis Club” is unlisted and membership is by referral only. Through her personal relationships and connections within Hollywood and the media, Cheryl Shuman has been named as one of the most influential women in the cannabis reform movement by international media.

Citigroup faces curbs on hedge fund sales (eFinancialNews)
The curbs, which haven’t previously been reported, result from the August 5 approval of a settlement between Citigroup Inc (NYSE:C) and the Securities and Exchange Commission of claims related to the bank’s earlier sale of certain debt products. The setback for Citigroup is partly due to timing. Other banks with similar settlements have been able to escape the restrictions because they came before a change in the law last year. Over the past two weeks, Citigroup has been sending letters to hedge fund firms informing them that the bank is no longer able to steer investors to their funds. In the letter, Citigroup said it is working to resolve the issue with the SEC. Under the rules, the SEC has to issue a waiver to allow Citigroup to resume hedge fund sales to clients.

Gin Lane property on the market for first time in 50 years (TheRealDeal)
A beachfront property on Southampton’s Gin Lane will hit the market for the first time in more than 50 years with an asking price of $50 million. The 4-acre parcel is next door to Wooldon Manor, which Scott A. Bommer, founder of hedge fund SAB Capital, bought for $75 million and then almost immediately sold for more than $80 million, the Wall Street Journal reported. Tim Davis of Corcoran Group, who handled the sale for Bommer, will also represent the owner of the property, William G. McKnight, according to the newspaper.

Cramer’s winning stock roster (CNBC)

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!